PathoGenesis IPO will support Phase III inhaled tobramycin trials.
PATHOGENESIS IPO WIL FUND INHALED TOBRAMYCIN DEVELOPMENT as well as other research programs at the Seattle-based start-up firm. PathoGenesis began Phase III clinical trials in July of PA-1005 to treat chronic pseudomonal bacterial lung infections in cystic fibrosis patients. PA-1005 is "a novel, stable, premixed formulation of the antibiotic tobramycin for delivery by inhalation," a Sept. 20 initial public offering prospectus explains.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth